Polycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study.

Abstract

Is maternal polycystic ovary syndrome (PCOS) associated with increased offspring risk of congenital heart defects? This study does not support a strong association between PCOS and an increased risk of congenital heart defects. In addition to affecting reproductive health, PCOS may involve insulin resistance. Maternal pregestational diabetes is associated with an increased risk of congenital heart defects and therefore PCOS may increase the risk of congenital heart defects in the offspring. In this nationwide cohort study, we used data from Danish health registers collected from 1995 to 2018. The study included 1302648 offspring and their mothers. Participants were live singleton offspring born during the study period. Information on maternal PCOS and offspring congenital heart defects was obtained from the National Patient Register. Logistic regression analysis was used to compute prevalence (odds) ratio (PR) of the association between PCOS and offspring congenital heart defects. Among 1302648 live-born singletons, 11804 had a mother with PCOS. Of these, 143 offspring had a congenital heart defect (prevalence 121 per 10000) as compared with 12832 among mothers without PCOS (prevalence 99 per 10000). The adjusted PR was 1.22, 95% CI 1.03-1.44 comparing prevalence of congenital heart defects in offspring of women with PCOS with offspring of women without. After adjusting for the potentially mediating effect of pregestational diabetes, the PR was 1.16, 95% CI 0.98-1.37. PCOS may be underdetected in the National Patient Register. However, we expect that the mothers that we identified with PCOS truly had PCOS, thus, the estimated associations are not likely to be affected by this misclassification. The study does not provide evidence to rule out a moderate or weak association. These findings provide reassurance to clinicians counselling pregnant women with PCOS that the disease does not pose a markedly increased risk of offspring congenital heart defects. The study was funded by the Novo Nordisk Foundation. M.L. reports personal fees from Dansk Lægemiddel Information A/S outside the submitted work. The remaining authors have no conflicts of interest. N/A.